Yes, dutasteride can be combined with alpha-blockers such as tamsulosin, but co-administration may increase the risk of low blood pressure. Blood pressure should be monitored, especially after the first few doses.
Most men notice a gradual reduction in urinary frequency and urgency within 3-6 months of consistent daily dosing, although individual response times vary.
Dutasteride is not age-restricted, but older men should have liver and kidney function evaluated before starting therapy, as impairment can affect drug metabolism.
Persistent sexual side effects should be discussed with a prescriber. In some cases, the dose may be adjusted, or an alternative therapy considered.
Dutasteride can lower PSA levels by about 50 %. Healthcare providers usually adjust PSA readings by doubling the measured value to interpret cancer screening accurately.
For most minor procedures, continuation is acceptable. However, surgeons may request temporary discontinuation for major surgeries to reduce bleeding risk, especially if combined with anticoagulants.
No. Dutasteride is contraindicated in women, particularly those who are pregnant or may become pregnant, due to the risk of fetal harm.
Dutasteride can be taken with or without food; however, consistency is recommended to maintain stable plasma levels.
Symptoms include swelling of the face, lips, tongue, or throat, difficulty breathing, and a widespread rash. Immediate medical attention is required.
Unused tablets should be returned to a pharmacy’s medication take-back scheme or disposed of according to local NHS guidelines to prevent accidental ingestion.
Dutasteride is a prescription-only medication used primarily in the management of benign prostatic hyperplasia (BPH). It belongs to the men’s health category and is marketed in the United Kingdom as a 0.5 mg oral pill. The active ingredient, dutasteride, works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), the more potent androgen that contributes to prostate growth.
Dutasteride is a 5-alpha-reductase inhibitor. Humans have three isoforms of this enzyme (type 1, type 2, and type 3); dutasteride blocks both type 1 and type 2, which together account for the majority of DHT production in the prostate and scalp. By reducing DHT levels, the drug slows the enlargement of prostate tissue, alleviating urinary symptoms associated with BPH.
Key pharmacologic points:
In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved dutasteride for the treatment of symptomatic BPH in men aged 18 years and older. The medication helps to:
While dutasteride is not licensed for hair loss in the UK, it has been studied off-label for androgenic alopecia (male-pattern baldness). Clinical trials have demonstrated that dutasteride can increase hair count and thickness more effectively than placebo, though the evidence is less extensive than for the related drug finasteride.
Disclaimer: Off-label use of dutasteride for hair loss must be supervised by a qualified healthcare professional, with a full assessment of potential risks and benefits.
These effects are generally mild and may improve with continued therapy, but any persistent sexual dysfunction should be discussed with a prescriber.
This article provides educational information about dutasteride and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
